Issue 5 - The Cancer Letter

<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Vol.

24

No.

5

May 25, 2001May 25, 2001

Free

DOWNLOAD THE PDF

Gleevec Produces 59% Response Rate In Gastrointestinal Stromal Tumors

Preoperative Chemo Doubles Survival In Locally Advanced Bladder Cancer

Gleevec Approval Sets Record For FDA Review: 73 Days

Advances Found In Treatment Of Aerodigestive Cancers

Silicone Implants Not Linked To Increased Risk Of Death

B-14 Trial: No Advantage To 10 Years Of Tamoxifen

NCI-Approved Clinical Trials Listed For April 2001

Recent Issues

Volume 52 | Issue 41 - November 06, 2026

Volume 52 | Issue 40 - October 30, 2026

Volume 52 | Issue 39 - October 23, 2026

Volume 52 | Issue 38 - October 16, 2026

Volume 52 | Issue 37 - October 09, 2026

Volume 52 | Issue 36 - October 02, 2026